Navigation Links
Luoxin Announces 2008 Third Quarterly Results; Profit Attributable to Shareholders Surged 62.9% to Approximately RMB 138,141,000
Date:10/28/2008

Obtained Shareholders' Approval on the Proposed Transfer of Listing of its

H Shares from GEM to the Main Board

HONG KONG, Oct. 28 /Xinhua-PRNewswire/ -- Shandong Luoxin Pharmacy Stock Co., Ltd. (HKEx: 8058), announced its third quarterly results for the nine months ended 30 September 2008, recording a strong growth in turnover and profit attributable to shareholders.

The Company's turnover rose 36.9% year-on-year to approximately RMB480,155,000, while gross profit increased by 45.6% to approximately RMB237,382,000. Profit attributable to shareholders surged by 62.9% to approximately RMB138,141,000. Basic earnings per share were RMB22.66 cents, representing an increase of 62.9% over the corresponding period in 2007.

As at 30 September 2008, the Company obtained a strong balance sheet with sufficient working capital and no debt.

During the period under review, the Company's Technology Center was certified as Province-Class Technology Center and joined forces with Shenyang Pharmacy University by establishing the Shenyang Pharmacy University and Luoxin Pharma post-doctorate workstation, Shenyang Pharmacy University and Luoxin Pharma education and training station, Shenyang Pharmacy University and Luoxin Pharma intern station. This cooperation has not only enhanced the technological advancement of Luoxin Pharma, but also served as a platform for technology interchange and nurture of talents, laying a solid foundation for the Company's future development.

In order to capture the huge market opportunity in the market, the Company's phase three capacity expansion plan has been completed and commenced operation. The production capacity of aseptic raw material and raw material for system-specific medicines has thus increased by 200 each.

Mr. Liu Baoqi, Chairman of Luoxin Pharma said, "The Company has recently obtained the shareholders' approval for the proposed transfer of listing of its H shares from GEM to the Main Board at the EGM and the respective Class Meetings on 24 October 2008. We believe that the listing on the Main Board not only helps further enhancing the profile of the Group and increases the trading liquidity of the Shares of the Company and recognition, but will also be of great benefit to future growth and business development of Luoxin Pharma in the long run."

For further information, please contact:

Porda International (Finance) PR Group

Ms. Kelly Fung

Tel: +852-3150-6763

Ms. Kate Lam

Tel: +852-3150-6738


'/>"/>
SOURCE Shandong Luoxin Pharmacy Stock Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. UCB Announces 2008 UCB Family RA Scholarship Program Recipients
2. QLT announces third quarter results for 2008
3. QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System
4. Response Biomedical Announces Insider Participation in Current Financing
5. American National Announces Third Quarter 2008 Results
6. Digestive Care, Inc. Announces the Complete Submission of the NDA for PANCRECARB(R) (pancrelipase)
7. U.S. Preventive Medicine(R) Announces Major Development for The Prevention Plan(TM)
8. Haemonetics Announces Promotion of Brian Concannon to CEO Effective April 2009
9. HLTH Corporation Announces Commencement of Its Tender Offer
10. ReachMD XM 157 Announces Medical Information Feature on Treatment Options for Management of Hyponatremia
11. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative ... National Family Partnership and the Drug Enforcement Administration as part of the National Red ... 10 winning schools who decorated their campuses with this year’s Red Ribbon Week theme: ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... they now offer a comprehensive in-house dental plan for all patients. Understanding that ... a plan that gives patients a number of perks, including discounts on many ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... Deloitte Wisconsin 75, an annual ranking and recognition of the largest closely held ... list, having ranked from 2008-2016. In addition, Standard Process was awarded the Talent ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center For ... announced the opening of a new residential mental health treatment program in Chino ... issues such as severe anxiety, depression, bi-polar disorder, and other related issues. , ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... and stylish design wanted by today’s consumers at an affordable price, is now ... says the new watch is “a game changer” when it comes to the ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für ... Apothekenbundes von Kenia eingeführt. Continue Reading ... ... Test! (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical wurde durch die ...
(Date:12/2/2016)... , December 2, 2016 Orthopedic Implants ... Support) is Expected to Gain a Significant Market Share Owing ... Ailments  ... According to a new ... Medical Implants Sterile Packaging: Clamshell Product Type Segment Projected to ...
(Date:12/2/2016)... December 2, 2016 On Thursday, the ... in red, while the Dow Jones Industrial Average managed to ... of US markets, which prompted Stock-callers this morning to look ... (NASDAQ: NUVA ), Smith & Nephew PLC (NYSE: ... NXTM ), and Cesca Therapeutics Inc. (NASDAQ: KOOL ...
Breaking Medicine Technology: